TERIFLUNOMIDE TEVA 14 mg FILM-COATED TABLETS

2. What you need to know before taking Teriflunomide Teva

Do not take Teriflunomide Teva

• if you are allergic to teriflunomide or any of the other ingredients of this medication (listed in section 6),
• if you have ever developed a severe skin rash or peeling of the skin, blisters, and/or ulcers in the mouth after taking teriflunomide or leflunomide,
• if you have severe liver problems,
• if you are pregnant, think you may be pregnant, or are breastfeeding,
• if you have a serious problem that affects your immune system, for example, acquired immune deficiency syndrome (AIDS),
• if you have serious bone marrow problems or a low number of white blood cells or red blood cells in the blood or a reduced number of platelets,
• if you have a severe infection,
• if you have severe kidney problems that require dialysis,
• if you have a low level of proteins in the blood (hypoproteinemia),

In case of doubt, ask your doctor or pharmacist before taking this medication.

Warnings and precautions

Consult your doctor or pharmacist before starting to take teriflunomide if:

• you have liver problems and/or if you drink large amounts of alcohol. Your doctor may perform blood tests to check your liver function before and during treatment. If the test results indicate a liver problem, your doctor may stop treatment with teriflunomide. See section 4.
• you have high blood pressure (hypertension), whether or not you are being treated for it. Teriflunomide may cause an increase in blood pressure. Your doctor will check your blood pressure before starting treatment and regularly during treatment. See section 4.
• you have an infection. Before you start taking teriflunomide, your doctor will make sure you have enough white blood cells and platelets in your blood. Since teriflunomide decreases the number of white blood cells in the blood, this may affect your ability to fight infection. Your doctor may perform blood tests to check your white blood cells if they think you have any infection. With teriflunomide treatment, viral infections, including oral herpes or shingles (herpes zoster), may occur. In some cases, serious complications have occurred. You should immediately inform your doctor if you suspect you have any symptoms of viral infection. See section 4.
• you have severe skin reactions.
• you have respiratory symptoms.
• you have weakness, numbness, and pain in hands and feet.
• you are going to be vaccinated
• you are taking leflunomide with teriflunomide
• you are being switched from or to teriflunomide
• a specific blood test (calcium level) is scheduled for you. A false decrease in calcium levels may be detected.

Respiratory reactions

Tell your doctor if you have cough and shortness of breath without explanation. Your doctor may perform additional tests.

Children and adolescents

Teriflunomide is not indicated for use in children under 10 years of age, as it has not been studied in patients with MS in this age group.

The warnings and precautions listed above also apply to children. The following information is important for children and their caregivers:

• pancreatitis has been observed in patients receiving teriflunomide. Your child's doctor may perform blood tests if they suspect pancreatitis.

Other medications and Teriflunomide Teva

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medications. This includes medications without a prescription.

In particular, tell your doctor or pharmacist if you are taking any of the following medications:

• leflunomide, methotrexate, and other medications that affect the immune system (often referred to as immunodepressants or immunomodulators)
• rifampicin (a medication used to treat tuberculosis and other infections)
• carbamazepine, phenobarbital, phenytoin for epilepsy
• St. John's Wort (a herbal medicine for depression)
• repaglinide, pioglitazone, nateglinide, or rosiglitazone for diabetes
• daunorubicin, doxorubicin, paclitaxel, or topotecan for cancer
• duloxetine for depression, urinary incontinence, or kidney disease in diabetics
• alosetron for severe cases of diarrhea
• theophylline for asthma
• tizanidine, a muscle relaxant
• warfarin, an anticoagulant to thin the blood (i.e., make it more fluid) to prevent clots
• oral contraceptives (containing ethinylestradiol, levonorgestrel)
• cefaclor, benzylpenicillin (penicillin G), ciprofloxacin for infections
• indomethacin, ketoprofen for pain or inflammation
• furosemide for heart disease
• cimetidine to reduce stomach acid
• zidovudine for AIDS
• rosuvastatin, simvastatin, atorvastatin, pravastatin for high cholesterol
• sulfasalazine for inflammatory bowel disease or rheumatoid arthritis
• cholestyramine for high cholesterol or relief of itching in liver disease
• activated charcoal to reduce the absorption of medications or other substances

Pregnancy andbreastfeeding

Do nottake teriflunomide if you are pregnant or think you may be pregnant. If you are pregnant or become pregnant while taking teriflunomide, you will increase the risk of having a baby with birth defects.

Women of childbearing age should not take this medication if they are not using reliable contraceptive methods.

If your daughter has her first menstrual period while taking teriflunomide, she should inform her doctor, who will provide specialized advice on contraceptive methods and potential risks in case of pregnancy.

Tell your doctor if you plan to become pregnant after stopping treatment with teriflunomide, as you need to make sure that most of this medication has been eliminated from your body before trying to become pregnant. The natural elimination of the active substance may take up to 2 years. This period can be reduced to a few weeks by taking certain medications to accelerate the elimination of teriflunomide from the body.

In any case, it must be confirmed by a blood test that the active substance has been sufficiently eliminated from your body, and you need confirmation from your doctor that the blood level of teriflunomide is low enough for you to become pregnant.

For more information on laboratory tests, contact your doctor.

If you suspect you are pregnant while taking teriflunomide or in the two years following the end of treatment, you should stop taking teriflunomide and contact your doctor immediatelyto perform a pregnancy test. If the test confirms pregnancy, your doctor may suggest treatment with certain medications to eliminate teriflunomide from your body quickly and sufficiently, as this may reduce the risk to your baby.

Contraception

You must use an effective contraceptive method during and after treatment with teriflunomide. Teriflunomide remains in the blood for a long time after stopping it. Continue to take effective contraceptive measures after stopping treatment.

• Do so until the levels of teriflunomide in the blood are low enough (your doctor will check)
• Consult your doctor about the best contraceptive method for you and in case you need to change methods

Do not take teriflunomide during breastfeeding, as teriflunomide passes into breast milk.

Driving and using machines

Teriflunomide may cause dizziness, which can affect your ability to concentrate and react. If you are affected, do not drive or use machines.

Teriflunomide Teva contains lactose and sodium

This medication contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.

This medication contains less than 1 mmol of sodium (23 mg) per tablet, which is essentially "sodium-free".

3. How to take Teriflunomide Teva

A doctor with experience in treating multiple sclerosis will supervise treatment with teriflunomide.

Follow the instructions for taking this medication exactly as indicated by your doctor. In case of doubt, consult your doctor again.

Adults

The recommended dose is one 14 mg tablet per day.

Children and adolescents (10 years of age and older)

The dose depends on body weight:

• children with a body weight over 40 kg: 14 mg once a day.
• children with a body weight of 40 kg or less: 7 mg once a day (Teriflunomide Teva is only available in 14 mg film-coated tablets, so the doctor will switch this category of patients to a different medication that contains teriflunomide).

Your doctor will instruct children and adolescents who reach a stable body weight over 40 kg to switch to a 14 mg tablet per day.

Form/Route of Administration

Teriflunomide is administered orally. Teriflunomide is taken once a day in a single dose at any time of day.

The tablet should be swallowed whole with water.

Teriflunomide can be taken with or without food.

If you take more Teriflunomide Teva than you should

If you have taken too much teriflunomide, call your doctor immediately. You may experience side effects similar to those described in section 4 (below).

If you think you have suffered an overdose and have any of these symptoms, inform your doctor immediately. You can also call the Toxicology Information Service, Tel. 91 562 0420

If you forget to take Teriflunomide Teva

Do not take a double dose to make up for forgotten doses. Take your next dose at the scheduled time.

If you stop taking Teriflunomide Teva

Do not stop treatment or change the dose of teriflunomide without consulting your doctor first.

If you have any other questions about the use of this medication, ask your doctor or pharmacist.

4. Possible side effects

Like all medications, this medication can cause side effects, although not everyone gets them.

The following side effects may occur with this medication.

Serious side effects

Some side effects can be or may become serious. If you experience any of these, tell your doctor immediately.

Common(may affect up to 1 in 10 people)

• pancreatitis that may include symptoms of abdominal pain, nausea, or vomiting (common in pediatric patients and uncommon in adult patients).

Uncommon(may affect up to 1 in 100 people)

• allergic reactions that could include symptoms of rash, hives, swelling of lips, tongue, or face, or sudden difficulty breathing
• severe skin reactions that could include symptoms of skin rash, blisters, fever, or ulcers in the mouth
• severe or life-threatening infections that could include symptoms such as high fever, chills, decreased urine flow, or confusion
• inflammation of the lungs that could include symptoms such as shortness of breath or persistent cough

Frequency not known (frequency cannot be estimated from the available data)

• severe liver disease that may include symptoms such as yellowing of the skin or whites of the eyes, darker than normal urine, unexplained nausea and vomiting, or abdominal pain.

Other side effectsmay occur with the following frequencies:

Very common(may affect more than 1 in 10 people)

• headache
• diarrhea, feeling sick
• increase in ALT (increase in certain liver enzymes in the blood) in blood tests
• thinning of hair

Common(may affect up to 1 in 10 people)

• flu, upper respiratory tract infection, urinary tract infection, bronchitis, sinusitis, sore throat and discomfort when swallowing, cystitis, viral gastroenteritis, tooth infection, laryngitis, fungal infection of the foot
• viral infections, including oral herpes and shingles (herpes zoster), with symptoms such as blisters, burning, itching, numbness, or pain in the skin, usually on one side of the upper body or face, and other symptoms, such as fever and weakness.
• laboratory values: a decrease in the number of red blood cells (anemia), changes in liver and white blood cells in blood tests (see section 2), as well as elevations in a muscle enzyme (creatine phosphokinase)
• mild allergic reactions
• feeling anxious
• tingling, feeling weak, numbness, or pain in the lower back or leg (sciatica); feeling numb, burning, tingling, or pain in hands and fingers (carpal tunnel syndrome)
• palpitations
• increase in blood pressure
• feeling sick (vomiting), toothache, pain in the upper abdominal region
• rash, acne
• pain in tendons, joints, bones, muscle pain (musculoskeletal pain)
• need to urinate more often than usual
• heavy periods
• pain
• lack of energy or weakness (asthenia)
• weight loss

Uncommon(may affect up to 1 in 100 people)

• mild decrease in the number of platelets (thrombocytopenia)
• increased sensitivity, especially in the skin; stabbing or pulsating pain in one or more nerves; problems in the nerves of arms and legs (peripheral neuropathy)
• changes in nails, severe skin reactions
• post-traumatic pain
• psoriasis
• inflammation of the mouth/lips
• abnormal levels of fats (lipids) in the blood
• inflammation of the colon (colitis)

Rare(may affect up to 1 in 1,000 people)

• inflammation or liver damage

Frequency not known(frequency cannot be estimated from the available data)

• pulmonary hypertension

Children (10 years of age and older) and adolescents

The side effects listed above also apply to children and adolescents. The following additional information is important for children, adolescents, and their caregivers:

Common(may affect up to 1 in 10 people)

• pancreatitis

Reporting side effects

If you experience any side effects, consult your doctor or pharmacist, even if they are side effects not listed in this package leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https//www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medication.

5. Storage of Teriflunomida Teva

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on the blister after “CAD” or “EXP”. The expiry date is the last day of the month shown.

This medicine does not require any special storage conditions.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help to protect the environment.

6. Package Contents and Additional Information

Composition of Teriflunomida Teva

• The active substance is teriflunomide. Each film-coated tablet contains 14 mg of teriflunomide.
• The other ingredients are lactose monohydrate, microcrystalline cellulose (E 460), corn starch, sodium starch glycolate (type A), hydroxypropylcellulose (E 463), colloidal anhydrous silica (E 551), sodium fumarate and stearate, hypromellose (E 464), titanium dioxide (E 171), talc (E 553b), macrogol (E 1521), aluminum lake indigo carmine (E 132).

Appearance of the Product and Package Contents

Teriflunomida Teva are blue, round film-coated tablets, approximately 6.6 mm in diameter and 4.1 mm in thickness, marked with “TV” on one face of the tablet and with “Y12” on the other face of the tablet.

Teriflunomida Teva is available in:

• Aluminum blister packs - OPA/Alu/PVC containing 10, 14, 28, 30, and 84 film-coated tablets or
• Single-dose perforated aluminum blister packs - OPA/Alu/PVC containing 10x1, 28x1, 30x1, and 84x1 film-coated tablets.

Only some pack sizes may be marketed.

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder

Teva B.V.

Swensweg 5,

2031GA Haarlem,

Netherlands

Manufacturer

Teva Operations Poland Sp. z o.o.

Mogilska 80 Str.

31-546 Krakow

Poland

or

Balkanpharma Dupnitsa AD

3 Samokovsko Shosse Str.

2600 Dupnitsa

Bulgaria

You can request more information about this medicine by contacting the local representative of the marketing authorization holder:

Teva Pharma, S.L.U.

C/ Anabel Segura, 11, Edificio Albatros B, 1ª planta,

Alcobendas, 28108 – Madrid

Spain

This medicine is authorized in the Member States of the European Economic Area under the following names:

Austria Teriflunomid ratiopharm 14 mg Filmtabletten

Belgium Teriflunomide Teva 14 mg Filmomhulde tabletten/comprimés pelliculés/Filmtabletten

Czech Republic Teriflunomide Teva

Germany Teriflunomid-ratiopharm 14 mg Filmtabletten

Denmark Teriflunomide Teva

Estonia Teriflunomide Teva

Spain Teriflunomida Teva 14 mg film-coated tablets EFG

Finland Teriflunomide ratiopharm 14 mg tablet, film-coated

France Tériflunomide Teva 14 mg, comprimé pelliculé

Croatia Teriflunomid Teva 14 mg film-coated tablets

Hungary Teriflunomide Teva 14 mg filmtabletta

Iceland Teriflunomide Teva

Italy Teriflunomide Teva

Lithuania Teriflunomide 14 mg film-coated tablets

Latvia Teriflunomide Teva 14 mg film-coated tablets

Netherlands Teriflunomide Teva 14 mg, filmomhulde tabletten

Norway Teriflunomide Teva

Poland Teriflunomide Teva

Portugal Teriflunomida Teva

Romania Teriflunomida Teva 14 mg film-coated tablets

Sweden Teriflunomide Teva

Slovenia Teriflunomid Teva 14 mg film-coated tablets

Slovakia Teriflunomid Teva 14 mg film-coated tablets

Date of the last revision of thisleaflet:September 2024

Other sources of information

Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/)

The most recently approved information (patient information leaflet) on this medicine is available by scanning the following QR code with a smartphone. The same information is also available on the following website (URL): https://cima.aemps.es/cima/DocsPub/16/3065